TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide informed consent signed by study patient or legally acceptable representative, as specified by health authorities and institutional guidelines;~2. Age ≥18 years;~3. Histologically or cytologically documented, advanced or metastatic Triple Negative Breast Cancer, histologically or cytologically documented, advanced or metastatic endometrial carcinoma, histologically or cytologically confirmed advanced or metastatic, unresectable adenocarcinoma of the colon or rectum.~4. Tumor tissue (archival or fresh tumor tissues as formalin-fixed paraffin-embedded blocks or approximately 15 unstained slides) for central laboratory assessment.~5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.~6. At least 1 measurable lesion as defined by RECIST v1.1.~Exclusion Criteria:~1. Has at screening any central nervous system metastasis and/or leptomeningeal disease.~2. Except for Cohort A, Prior therapy targeting CTLA-4, PD-1, PD-L1 or programmed cell death protein ligand-2 (PD-L2) or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.~3. Prior treatment with a VEGFR-TKI or anti-VEGFR antibody (eg, ramucirumab).~4. Except for Cohort D, prior treatment with an anti-VEGFR antibody (eg, bevacizumab).~5. Tumor tissue (archival or fresh tumor tissues as formalin-fixed paraffin-embedded blocks or approximately 15 unstained slides) for central laboratory assessment.~6. Active autoimmune diseases or history of autoimmune diseases that may relapse, or history of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 (Type: EXPERIMENTAL): Approximately 6-12 patients with locally advanced or metastatic solid tumors will be enrolled to receive fruquintinib in combination with tislelizumab and assessed for DLTs during the 28-day DLT observation period
- Part 2 (Type: EXPERIMENTAL): Patients will be enrolled to one of the following expansion cohorts:~* Cohort A: TNBC (immuno-oncology \[IO\]-treated in the metastatic setting)~* Cohort B: TNBC (IO-Naïve in the metastatic setting)~* Cohort C: EC~* Cohort D: MSS CRC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Rehabilitation Before Lung Cancer Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
1. Patient is scheduled to undergo NSCLC resection: video assisted thoracoscopy (VATS) or open thoracotomy for: limited resection, lobectomy, or pneumonectomy. Surgery must not be scheduled to take place \< 3 weeks after registration.~2. Patient has a doctor diagnosis of COPD.~3. Patient is a current or ex-smoker with a smoking history of ≥ 10 pack years. (Calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. For example, 1 pack-year is equal to smoking 20 cigarettes (1 pack) per day for 1 year, or 40 cigarettes per day for half a year, and so on).~4. Age ≥ 18 yrs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pulmonary Rehabilitation (PR) (Type: EXPERIMENTAL): Patients will receive 10 in-clinic sessions of preoperative Pulmonary Rehabilitation (PR) two weeks prior to surgery. Patients will receive a Participant Manual demonstrating and explaining the rehabilitation process. Patients will also receive a log for recording their efforts and notes for every day until the day of surgery. A video recording of the intervention from start to finish will be provided to all patients. The video recording should be played in all 10 sessions at the registering site. The PR sessions will include breathing awareness, upper and lower extremity exercise, instructions for inspiratory muscle training using the PFlex valve, practice at home and goal setting. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
- Standard of Care (Type: ACTIVE_COMPARATOR): Patients will receive a pedometer to monitor their daily steps and a pamphlet with exercises plus the standard course of care for patients undergoing lung resection surgery. The patients will not be asked to return the pedometer. The local institutional coordinator will go over the use of the pedometer and the exercise materials with the patient. The patients will be asked to keep a log of their pre-operative steps and mail the log to the registering site. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Diagnosis of breast carcinoma with HER-2 overexpression~* At least one measurable brain metastasis~* Patients for whom, according to investigator assessment, whole brain radiotherapy is the best therapeutic option~* Performance status (WHO) \</=2~* Life expectancy \>/=3 months~Exclusion Criteria:~* Presence of neoplastic meningitis~* Any prior radiotherapy to the brain~* Patients for whom, according to investigator assessment, stereotactic radiotherapy is the best therapeutic option~* Previous neoplasms, other than breast carcinoma, within 5 years since enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Monotherapy (Type: EXPERIMENTAL): Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Didgeridoo Practice on UA Obstruction Levels in Moderate OSA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* moderate OSA, non obese~Exclusion Criteria:~* not willing play didgeridoo age\<18 significant lung, cardiac disease neuromuscular disease psychiatric disorders drugs with influence on respiratory drive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- didgeridoo practice (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of renal allograft with current actinic keratosis I or II or successfully treated actinic keratosis III (inclusion possible immediately after completed wound healing from surgical excision), invasive squamous cell carcinoma (SCC), basal cell carcinoma and/or premalignant neoplastic skin lesions~* Age 18 years and older~* Minimum period of 6 month after renal transplantation~* Stable renal function and a calculated creatinine clearance of at least 40 ml/min~* Written informed consent~* Proteinuria ≤ 800 mg/d at time of enrolment~* Successfully treated solid tumor (no recurrence or metastasis in the last 2 years)~Exclusion Criteria:~* Current Sirolimus- or Everolimus- intake~* Instable graft function (creatinine clearance \< 40 ml/min)~* Graft rejection within the 3 previous months~* Proteinuria \> 800 mg/d~* Non-controlled hyperlipidemia (Cholesterol \>7,8 mmol/l, Triglycerides \> 4)~* Leucopenia \< 2500/nl~* Thrombocytopenia \< 90/nl~* Pregnancy or breastfeeding~* Women of childbearing age without highly effective contraception (= defined as those which result in a low failure rate (i.e. less than 1 % per year))~* Known allergy to macrolides~* Current participation in other studies~* Refusal to sign informed consent form~* Neoplasm other than defined as inclusion criteria~* All contraindications to SRL (see package insert, appendix)~* Persons who are detained officially or legally to an official institute

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.
- 2 (Type: ACTIVE_COMPARATOR): Patients will stay on their previous immunosuppressive regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria for Aim 1:~* Scheduled to receive therapy with trastuzumab plus chemotherapy as part of standard care~* Have one or more breast tumors visualized by conventional PET/CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study; PET/CT should be within a week prior to 18-F FMAU~Inclusion criteria for Aim 2:~* Have been diagnosed with a HER2+ invasive cancer of the breast~* Scheduled to receive pre-operative therapy with trastuzumab plus chemotherapy as part of standard care~* Have one or more breast tumors visualized by conventional PET/CT, CT or MRI prior to the PET FMAU study; PET/CT should be within a week prior to 18-F FMAU~Exclusion Criteria:~* Have undergone chemotherapy or radiation therapy within the previous one month~* Women of childbearing potential, unless they have had a negative urine human chorionic gonadotropin (HCG) within the previous 24 hours of the procedure~* Patients who have had surgery at the site of the suspected lesion within 1 month

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (fluorine F 18-clevudine PET/CT) (Type: EXPERIMENTAL): Patients receive fluorine F18-clevudine IV over 1 minute and then undergo PET/CT scan at baseline. Patients with HER2+ breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Metformin on Frailty in 12 Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 60 years~* Stable CAD~* Prediabetes (one of the following criteria should be met)~  * Fasting plasma glucose: 100-126 mg/dL~ * HbA1C: 5.7-6.4~* Frailty (Short Physical Performance Battery: Score \<9)~* Able to return for follow-up~* Written informed consent~Exclusion criteria:~* Pre-existing or new-onset diabetes~* Any active malignancy, hematological disorder, post organ transplant, immunocompromised~* Cancer requiring treatment in the past 3 years (other than non-melanoma skin cancer)~* Dementia \[mini mental state examination (MMSE \<20)\]~* Disability (need for assistance in \>2 of any six activities on Katz activities of daily living (ADL)46~* Prior stroke with disability~* Acute coronary syndrome \<3months or participating in cardiac rehabilitation~* Severe Parkinson's~* Hepatic insufficiency and/or chronic liver disease (cirrhosis)~* Chronic kidney disease (GFR \< 45 mL/min)~* Taking metformin for any indication~* Acute alcohol intoxication~* Known hypersensitivity to metformin hydrochloride~* Acute/chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin 500mg tablet by mouth, every 6 to 8 hours for one year
- Placebo (Type: ACTIVE_COMPARATOR): Placebo by mouth every 6 to 8 hours for one year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Vaccination on Th2 Immunity in Infancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from parent/guardian~* General good health without other known need for blood draws that would conflict with the study volume requirements~* Aged 5 months - 7 months, any race/ethnicity, any gender~* Subjects must not have yet received their third DTaP vaccination, which typically is given at 6 months of age. Subjects must have previously received two doses of the DTaP vaccination, at ages 2 months and 4 months~* Willingness to return for follow-up testing as defined in the protocol and consent if screening tests indicate eligibility~* Group 1 participants must have all of the following:~  * A negative skin prick test to egg, milk, and peanut~ * A negative IgE to egg, milk, and peanut~* Group 2 participants must have all of the following:~  * A positive family history of allergic disease~ * Atopic Dermatitis not requiring prescription medication~ * A positive IgE to milk, egg, and/or peanut~If Group 1 enrollment is completed first, participants must have all of the following to be enrolled in Group 2:~* A family history of atopy~* Atopic dermatitis not requiring prescription medication~If Group 2 enrollment is completed first, participants must have all of the following to be enrolled in Group 1:~-No personal or family history of atopic disease~Exclusion Criteria:~* History of anemia requiring any treatment~* Previous allergic reaction to any food, defined as itching, rash, hives, swelling, vomiting, diarrhea, sneezing, rhinorrhea, wheezing, breathing difficulty, or passing out immediately after food ingestion.~* Evidence of non-IgE-mediated reaction to milk or soy (i.e. milk/soy protein intolerance) or evidence of food protein induced enterocolitis syndrome (FPIES)~* Severe atopic dermatitis (liberally defined as requiring prescription medication)~* Unable to obtain serum sample for determination of egg, milk and peanut IgE levels~* Use of short-acting anti-histamines (diphenhydramine, etc.) more than one time within 3 days of skin testing or on the day of skin testing~* Any history of intravenous or oral steroid medication~* Known underlying immune defect/deficiency or bleeding disorder

- Gender: ALL
- Minimum Age: 5 Months
- Maximum Age: 7 Months
- Healthy Volunteers: t

Study Arms:
- Positive blood test to milk, egg, and/or peanut (Type: None): Family history to atopy
- Negative blood test to allergy (Type: None): A negative skin prick test to egg, milk, and peanut and a negative Immunoglobulin E (IgE) to egg, milk, and peanut.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oxybutynin and Omega-3 for OAB (Overactive Bladder)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women between the ages of 18-85; Desiring treatment for symptoms of urinary frequency, defined as \>8 voids/day and/or nocturia \> 1 void/night or urge incontinence episodes of \>1/day~Exclusion Criteria:~Bleeding disorder; Uncontrolled diabetes; Hypotension; Liver disease, such as hepatitis A/B/C, cirrhosis, acute fatty liver, liver tumors; Post voiding residual (PVR) \> 150 on more than one occasion; Uncontrolled narrow-angle glaucoma; Hematuria of unknown cause; Obstructive uropathy; Known hypersensitivity to study medications; Recent use of study/omega 3 or anticholinergic medication in the prior 3 weeks with an inability to discontinue this medication; Planning any surgery in the 6 weeks of study duration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Omega- 3 Fatty Acid (Type: EXPERIMENTAL): The patient will receive oxybutynin 5 mg twice daily (BID). The patients in the study group will receive a 0.9 gm capsule of Omega-3 BID. The amount of medication was chosen based on dosage used in prior studies and the current FDA recommendations to not exceed 2gm/day of omega-3 in dietary supplementation.
- Placebo (Type: PLACEBO_COMPARATOR): Seagate® Extra Virgin Olive oil capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tenodesis vs. Self-locking Tenotomy in Long Head of the Biceps Tendon Lesions: A Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary indication is for pathology of the LHBT or biceps-labrum complex~* Age 40-80~* Ability to comply with a standardized postoperative protocol~* Willing and able to provide consent~Exclusion Criteria:~* Associated rotator cuff tear requiring arthroscopic repair~* Pregnant patient~* Age \<40 years~* Previous shoulder surgery~* Unable to speak English or perform informed consent

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Biceps self-locking T tenotomy (Type: EXPERIMENTAL): None
- Biceps tenodesis (control) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Two Pneumatic Compression Devices in the Treatment of Lower Extremity Lymphedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be ≥ 18 years old or legal age in host country.~* Subjects must have a diagnosis of primary or secondary late Stage 2 or 3 unilateral or bilateral lower extremity lymphoedema.~* At time of initial evaluation, individuals must be at least 3 months post-surgery, chemotherapy and/or radiation treatment for cancer if applicable.~* If subjects were treated in a clinic setting for lymphoedema (Phase 1 treatment) they must be at least 3 months post completion of their acute care.~Exclusion Criteria:~* Diagnosis of active or recurrent cancer, or less than 3 months at the time of initial evaluation from the completion of chemotherapy, radiation therapy or primary surgery for the treatment of cancer.~* Diagnosis of acute infection. The source of the infection must be treated for 2 weeks prior to admittance into the study.~* Diagnosis of acute thrombophlebitis (in last 2 months)~* Diagnosis of peripheral arterial disease (PAD): PAD is defined as an Ankle Brachial Index (ABI), of 0.7 or lower.~* Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months~* Diagnosis of pulmonary edema~* Diagnosis of congestive heart failure (uncontrolled)~* Diagnosis of chronic kidney disease with a Glomerular Filtration Rate (GFR) of less than 30 mls per minute.~* Patients with poorly controlled asthma (i.e. those with severe persistent symptoms throughout the day, night time awakenings several times per week, use of a beta2 agonist inhaler several times per day and those whose normal activity is extremely limited).~* Pregnancy~* Any condition where increased venous and lymphatic return is undesirable~* Inability or unwillingness to participate in all aspects of study protocol and/or inability to provide informed consent~* Currently participating in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced PCD (Type: EXPERIMENTAL): The use of an advanced PCD device to reduce and maintain limb volume
- Simple PCD (Type: ACTIVE_COMPARATOR): The use of the Simple PCD is to reduce and maintain limb volume

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy